Amgen buying deCODE Genetics for $415 million

December 10, 2012 by Linda A. Johnson

Biotech pioneer Amgen Inc., in a bid for a big edge in using people's genetic information to find better ways to attack diseases, is buying human genetics research and analytics leader deCODE Genetics for $415 million.

Amgen, the world's largest by revenue, and deCODE, based in Reykjavik, Iceland, announced the all-cash deal Monday.

DeCODE, founded in 1996, has discovered for dozens of diseases, ranging from cardiovascular disease to cancer.

Probably its key asset—and the reason for the deal—is deCODE's huge database of the genetic and medical information of Iceland's population. That data can help researchers find links between genetic variations and characteristics that increase a person's risk of getting a particular disease and also affect patients' response to a drug.

" has built a world-class capability in the study of the genetics of human disease. This capability will enhance our efforts to identify and validate human disease targets," Amgen CEO Robert Bradway said in a statement.

"This fits perfectly with our objective to pursue rapid development of relevant molecules that reach the right disease targets while avoiding investments in programs based on less well-validated targets," Bradway added.

That's important because the vast majority of experimental drugs, after years of expensive testing, eventually turn out not to work well or to have dangerous side effects. Drugmakers worldwide are trying to find ways to make their drug-development process more efficient to avoid spending tens of millions of dollars testing drugs that end up failing.

UBS Securities analyst Matthew Roden wrote in a note to investors that Amgen management stressed to him that being able to more efficiently identify and confirm targets for future development would help the company spot promising candidates, as well as likely failures, earlier.

"It is not surprising that Amgen is building out this R&D capability," given that some of its key experimental drugs were identified based on human genetics work, Roden wrote.

He has a "Buy" rating for Amgen and a 12-month share price target of $96, higher than its shares have ever been and significantly above its $89.95 peak over the last year. Roden noted Amgen will use off-shore cash for the deal and will not issue debt to cover it.

The board of Amgen, based in Thousand Oaks, California, has approved the deal, which does not need regulatory approval. The transaction is expected to close before year's end.

"We believe Amgen's focus and ability to incorporate our genetic research into their research and development efforts will translate our discoveries into meaningful therapies for patients," Dr. Kári Stefánsson, deCODE's founder and CEO, said in a statement.

Amgen, a biotechnology pioneer since 1980, focuses on developing powerful biologic medicines—drugs produced by living cells rather than by mixing chemicals in vats—for cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. Among its products are the anemia drugs Aranesp and Epogen, Enbrel for immune disorders and Prolia for osteoporosis.

Amgen reported sales of $15.6 billion last year and net income of $3.7 billion.

Shares of rose 73 cents to $89.05 in afternoon trading after rising as high as $89.28 per share earlier. That was just shy of its 52-week high of $89.95 set in mid-October.

Explore further: Amgen buys Micromet for anti-leukemia drug

shares

Related Stories

Amgen buys Micromet for anti-leukemia drug

January 26, 2012
Biotech giant Amgen said Thursday it was buying the German-American cancer research firm Micromet, giving it access to Micromet's promising leukemia therapy.

Recommended for you

The 16 genetic markers that can cut a life story short

July 27, 2017
The answer to how long each of us will live is partly encoded in our genome. Researchers have identified 16 genetic markers associated with a decreased lifespan, including 14 new to science. This is the largest set of markers ...

A rogue gene is causing seizures in babies—here's how scientists wants to stop it

July 26, 2017
Two rare diseases caused by a malfunctioning gene that triggers seizures or involuntary movements in children as early as a few days old have left scientists searching for answers and better treatment options.

Scientists provide insight into genetic basis of neuropsychiatric disorders

July 21, 2017
A study by scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) is providing insight into the genetic basis of neuropsychiatric disorders. In this research, the first mouse model of a mutation ...

Scientists identify new way cells turn off genes

July 19, 2017
Cells have more than one trick up their sleeve for controlling certain genes that regulate fetal growth and development.

South Asian genomes could be boon for disease research, scientists say

July 18, 2017
The Indian subcontinent's massive population is nearing 1.5 billion according to recent accounts. But that population is far from monolithic; it's made up of nearly 5,000 well-defined sub-groups, making the region one of ...

Mutant yeast reveals details of the aberrant genomic machinery of children's high-grade gliomas

July 18, 2017
St. Jude Children's Research Hospital biologists have used engineered yeast cells to discover how a mutation that is frequently found in pediatric brain tumor high-grade glioma triggers a cascade of genomic malfunctions.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.